US4383985A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Breast cancer antigens
Assignee: Hoffmann La Roche Inc
•
Filing: 1980-07-11
•
Granted: 1983-05-17
•
Expires: 2000-07-11
Abstract
Abstract Tumor associated antigens are disclosed in both crude and pure form which are specific to human breast cancer. The antigens are designated BCA. Antisera, radiolabeled antigens and antisera, as well as methods for the detection of circulating BCA are also disclosed. Methods for the extraction of BCA also form part of the invention. A diagnostic kit for the detection of circulating BCA, especially one suitable for use in as radioimmunoassay is also disclosed.
Inventors
- 👤 Alberto Bartorelli
- 👤 Roberto Accinni
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 21:02
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/575; G01N33/57515; A; A61; A61K; A61K39/00; Y; Y10; Y10S; Y10S435/00; Y10S435/975; Y10S436/00; Y10S436/804; Y10S436/811; Y10S436/813; Y10S530/00; Y10S530/806; Y10S530/827; Y10S530/828; Y10S530/829; Y10S530/83
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
52 words
Breast cancer antigens, designated "BCA", and characterized as follows: (a) being endogenous to and extractable with a glycoprotein solvent from human primary breast carcinomas, (b) unreactive with carcinoembryonic antigen antiserum, (c) reactive only with antiserum produced by antigens extracted from human primary breast carcinomas, and (d) essentially free of other endogenous material.
Claim 2
Dependent Claim
52 words
Breast cancer antigens, designated "BCA", and characterized as follows: (a) being endogenous to and extractable with a glycoprotein solvent from human primary breast carcinomas, (b) unreactive with carcinoembryonic antigen antiserum, (c) reactive only with antiserum produced by antigens extracted from human primary breast carcinomas, and (d) essentially free of other endogenous material.
Claim 3
Dependent Claim
12 words
BCA-antiserum specific to BCA, said BCA being as claimed in claim 1.
Claim 4
Dependent Claim
10 words
Radiolabeled BCA, said BCA being as claimed in claim 1.
Claim 5
Dependent Claim
10 words
Radiolabeled BCA-antiserum, said BCA being as claimed in claim 1.
Claim 6
Dependent Claim
15 words
Radiolabeled BCA labeled with I 125 , said BCA being as claimed in claim 3.
Claim 7
Dependent Claim
11 words
Enzyme labeled BCA, said BCA being as claimed in claim 1.
Claim 8
Dependent Claim
98 words
An immunoassay method for detecting breast cancer antigens, designated BCA, said BCA being as claimed in claim 1 and circulating in a serum or plasma sample, which method comprises: (a) adding a specific amount of BCA-antiserum to the sample, (b) incubating the resulting mixture of step (a), (c) adding a specific amount of labeled BCA to the mixture, (d) incubating the mixture, (e) separating the resulting BCA-anti BCA complexes from free BCA, and (f) measuring the activity of the labeled BCA of either the complexes or the free BCA, in order to detect the BCA of the sample.
Claim 9
Dependent Claim
15 words
A method as claimed in claim 7 wherein the labeled BCA is radioactively labeled BCA.
Claim 10
Dependent Claim
14 words
A method as claimed in claim 7 wherein labeled BCA is fluorescent labeled BCA.
Claim 11
Dependent Claim
80 words
A diagnostic test kit for the detection of breast cancer antigens, designated BCA, in a serum or plasma sample, said BCA being as claimed in claim 1, the kit comprising in combination: (a) a container containing a specific amount of BCA-antiserum, and (b) another container containing a specific amount of radiolabeled BCA, said BCA-antiserum and radiolabeled BCA being capable of providing radiolabeled immunocomplexes containing the BCA of the sample when the sample is treated with said BCA-antiserum and radiolabeled BCA.
Claim 12
Dependent Claim
15 words
A diagnostic kit as claimed in claim 10 wherein the radiolabel is I 125 .
Claim 13
Dependent Claim
78 words
A diagnostic test kit for the detection of breast cancer antigens (BCA) in a serum or plasma sample, said BCA being as claimed in claim 1, the kit comprising in combination: (a) a container containing a specific amount of BCA, and (b) another container containing a specific amount of radiolabeled BCA-antiserum, said BCA and radiolabeled BCA-antiserum being capable of providing radiolabeled immunocomplexes containing the BCA of the sample when sample is treated with said BCA and radiolabeled BCA-antiserum.
Claim 14
Dependent Claim
15 words
A diagnostic kit as claimed in claim 12 wherein the radiolabel is I 125 .
Claim 15
Dependent Claim
67 words
Breast cancer antigens extracted from human primary breast carcinoma by a process comprising: (a) extracting homogenized human primary breast carcinoma material with a glycoprotein solvent; (b) centrifuging said extract; (c) dialyzing the resultant supernate; (d) lyophilizing the resultant dialysate; (e) resuspending the resultant lyophilized dialysate in a buffered saline solution; (f) subjecting the resulting suspension to gel filtration; and isolating the fractions containing said breast cancer antigens.
Claim 16
Dependent Claim
67 words
Breast cancer antigens extracted from human primary breast carcinoma by a process comprising: (a) extracting homogenized human primary breast carcinoma material with a glycoprotein solvent; (b) centrifuging said extract; (c) dialyzing the resultant supernate; (d) lyophilizing the resultant dialysate; (e) resuspending the resultant lyophilized dialysate in a buffered saline solution; (f) subjecting the resulting suspension to gel filtration; and isolating the fractions containing said breast cancer antigens.
Claim 17
Dependent Claim
76 words
Breast cancer antigens of enhanced purity obtained by a process which comprises: (a) subjecting the isolated fractions containing breast cancer antigen obtained in step (f) of claim 14 to chromatography on a diethylaminoethyl cellulose column (DEAE) and collecting from the DEAE the fractions containing said breast cancer antigens; (b) dialyzing the DEAE collected fractions; (c) subjecting the resulting dialysate to gel filtraction; and (d) isolating the fraction of the gel filtration containing said breast cancer antigens.
Claim 18
Dependent Claim
13 words
Breast cancer antigens according to claims 14 or 15, which antigens are radiolabeled.
Claim 19
Dependent Claim
13 words
Breast cancer antigens according to claim 16, wherein the radiolabel is 125 I-iodine.
Claim 20
Dependent Claim
14 words
Breast cancer antigens according to claims 14 or 15, which antigens are enzyme labeled.
Claim 21
Dependent Claim
22 words
Breast cancer antigen according to claim 14, wherein in step (a) extraction is performed on a lyophilized homogenized human primary breast carcinoma.
Claim 22
Dependent Claim
66 words
A process for the extraction of breast cancer antigen (BCA) from human primary breast carcinoma, the process comprising: (a) extracting homogenized human primary breast carcinoma material with a glycoprotein solvent; (b) centrifuging the resulting extract; (c) dialyzing the resulting supernate; (d) lyophilizing the resulting dialysate; (e) resuspending in a buffered saline solution; (f) submitting the suspension to gel filtration; and isolating the resulting fractions containing BCA.
Claim 23
Dependent Claim
66 words
A process for the extraction of breast cancer antigen (BCA) from human primary breast carcinoma, the process comprising: (a) extracting homogenized human primary breast carcinoma material with a glycoprotein solvent; (b) centrifuging the resulting extract; (c) dialyzing the resulting supernate; (d) lyophilizing the resulting dialysate; (e) resuspending in a buffered saline solution; (f) submitting the suspension to gel filtration; and isolating the resulting fractions containing BCA.
Claim 24
Dependent Claim
46 words
A process according to claim 20 further comprising: (a) subjecting the BCA obtained in step (f) of claim 20 to chromatography on a diethylaminoethyl cellulose column and collecting the fractions containing said breast cancer antigens; (b) dialyzing the collected fractions; and (c) collecting the resultant dialysate.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-05-16 | 1986-11-15 | 1987-05-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-05-16 | 1990-11-15 | 1991-05-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-05-16 | 1994-11-15 | 1995-05-17 | $7700.00 | Window Closed / Lapsed |